Functional mutation analysis of EGFR family genes and corresponding lymph node metastases in head and neck squamous cell carcinoma

Clinical and Experimental Metastasis

Volumn 29, Issue 1, 2012, Pages 19-25

  Hama, Takanori ^a   Yuza, Yuki ^a   Suda, Toshihito ^a   Saito, Yoshimichi ^a   Norizoe, Chihiro ^a   Kato, Takakuni ^a   Moriyama, Hiroshi ^a   Urashima, Mitsuyoshi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EGFR; HER2; HER3; HER4; HNSCC; Lymph node metastases

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PRIMER DNA;

ADULT; AGED; ARTICLE; DNA SEQUENCE; FEMALE; GENE SEQUENCE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA; ALLELE; GENETICS; HEAD AND NECK TUMOR; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY;

AGED; ALLELES; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; DNA PRIMERS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84856013039     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-011-9425-5     Document Type: Article

References (18)

1. Karamouzis MV, Grandis JR, Argiris A (2007) Therapies directed against epidermal growth factor receptor in aerodige stive carcinomas. JAMA 4:298(1):70-82 (Pubitemid 47026772)
2. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139 (Pubitemid 38637993)
3. Hama T, Yuza Y, Saito Y et al (2009) Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncol 14:900-908
4. Fan Y-X, Wong L, Ding J, Spiridonov NA, Johnson RC et al (2008) Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism. J Biol Chem 283(3):1588-1596
5. Kobayashi S, Ji H, Yuza Y et al (2005) An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65(16):7096-7101 (Pubitemid 41161238)
6. Yuza Y, Glatt KA, Jiang J et al (2007) Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Therapy 6:661-667 (Pubitemid 47328344)
7. O-Uchi J, Sasaki H, Morimoto S, et al (2008) Interaction of alpha1-adrenoceptor subtypes with different G proteins induces opposite effects on cardiac L-type Ca2+ channel. Circulation Res 102:1378-1388
8. Lee JW, Soung YH, Seo SH et al (2006) Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 12(1):57-61 (Pubitemid 43166176)
9. Kim HH, Vijapurkar U, Hellyer NJ et al (1998) Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J 334:189-195 (Pubitemid 28420988)
10. Soung YH, Lee JW, Kim SY et al (2006) Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 118(6):1426-1429
11. Gow C-H, Chang Y-L, Hsu Y-C et al (2009) Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naïve non-small-cell lung cancer. Ann Oncol 20(9):696-702
12. Schmid K, Oehl N, Wrba F et al (2009) EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding loco-regional lymph node metastases. Clin Cancer Res 15(14): 4554-4560
13. Yokoyama T, Kondo M, Goto Y et al (2006) EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci 97(8): 753-759 (Pubitemid 43983788)
14. Zhiwei Y, Titus JB, Susumu K et al (2007) Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res 67:10417-10427
15. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578 (Pubitemid 43209104)
16. Cohen EE, Rosen F, Stadler WM et al (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21(10):1980-1987 (Pubitemid 46606387)
17. Soulieres D, Senzer NN, Vokes EE et al (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, inpatients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22(1): 77-85 (Pubitemid 41095117)
18. Siu LL, Soulieres D, Chen EX et al (2007) Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a princess Margaret hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 25(16): 2178-2183 (Pubitemid 46954640)